The Board of Directors of Roivant Sciences Ltd. has authorized a buyback plan on April 2, 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.16 USD | +0.31% | -4.01% | -0.85% |
04-05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
04-04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.85% | 8.97B | |
+29.42% | 684B | |
+30.34% | 568B | |
-3.97% | 361B | |
+17.63% | 329B | |
+4.21% | 284B | |
+16.21% | 240B | |
+9.66% | 208B | |
-6.83% | 200B | |
+7.13% | 166B |
- Stock Market
- Equities
- ROIV Stock
- News Roivant Sciences Ltd.
- Roivant Sciences Ltd. authorizes a Buyback Plan.